Intellia Therapeutics NTLA
$10.00 +$0.48 (+5.04%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.00 +0.01%
Open$9.34
Prev close$9.52
Day range$9.30 – $10.40
Volume15.19M
Market cap$1.40B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$7.16M-48.0% YoY
Operating profit-$122.33M-9.7% YoY
Net profit-$127.49M-25.8% YoY
Diluted EPS-$0.91+1.1% YoY
Free cash flow-$86.32M-12.2% YoY
Operating cash flow-$85.43M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-821.2%
Net margin-805.7%
Return on equity-62.6%
Return on assets-46.6%
Return on invested capital-53.2%
Current ratio6.31
Liabilities / assets32.1%
Cash & investments$474.11M
Total debt$209.17M
Net cash (debt)$264.95M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $7.16M | $7.66M | $15.05M | $67.67M | $23.02M |
| Total Operating Revenue | $7.16M | $7.66M | $15.05M | $67.67M | $23.02M |
| Operating Expense | $129.49M | $120.42M | $115.58M | $508.66M | $121.73M |
| Selling and Admin Expenses | $46.14M | $37.82M | $34.84M | $119.80M | $33.08M |
| -General & Admin Expense | $46.14M | $37.82M | $34.84M | $119.80M | $33.08M |
| Research & Development | $83.35M | $82.60M | $80.74M | $388.86M | $88.65M |
| Operating Profit | -$122.33M | -$112.76M | -$100.53M | -$440.99M | -$98.71M |
| Net Non-Operating Interest Income (Expense) | $5.23M | $5.80M | $5.21M | $29.20M | $6.48M |
| Non-Operating Interest Income | $5.84M | $5.80M | $5.21M | $29.20M | $6.48M |
| Non-Operating Interest Expense | $611,000.00 | – | – | – | – |
| Other Income (Expense) | -$10.39M | $329,000.00 | -$904,000.00 | -$899,000.00 | -$3.55M |
| Gain on Sale of Security | -$10.39M | $329,000.00 | -$904,000.00 | -$899,000.00 | -$3.55M |
| Pretax Profit | -$127.49M | -$106.63M | -$96.23M | -$412.69M | -$95.79M |
| Net Profit | -$127.49M | -$106.63M | -$96.23M | -$412.69M | -$95.79M |
| Profit from Continuing Operations | -$127.49M | -$106.63M | -$96.23M | -$412.69M | -$95.79M |
| Net Income to Parent Company | -$127.49M | -$106.63M | -$96.23M | -$412.69M | -$95.79M |
| Net Income to Common Stockholders | -$127.49M | -$106.63M | -$96.23M | -$412.69M | -$95.79M |
| Basic EPS | -$0.91 | -$0.80 | -$0.81 | -$3.81 | -$0.83 |
| Diluted EPS | -$0.91 | -$0.80 | -$0.81 | -$3.81 | -$0.83 |
| Earnings from Equity Interest | – | – | – | $0.00 | – |
| Special Income (Charges) | – | – | – | $0.00 | – |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $902.56M | $857.16M | $758.78M | $842.13M | $842.13M |
| Total Current Assets | $506.35M | $527.83M | $466.45M | $527.71M | $527.71M |
| Cash and Cash Equivalents & Short-Term Investments | $474.11M | $437.76M | $375.99M | $449.88M | $449.88M |
| -Cash and Cash Equivalents | $156.10M | $106.13M | $134.70M | $155.46M | $155.46M |
| -Short Term Investments | $318.01M | $331.63M | $241.29M | $294.42M | $294.42M |
| Receivables | $7.50M | $7.32M | $9.13M | $9.47M | $9.47M |
| -Accounts Receivable | $7.50M | $7.32M | $9.13M | $9.47M | $9.47M |
| Other Current Assets | $24.74M | $82.75M | $81.33M | $68.36M | $68.36M |
| Total Non-Current Assets | $396.21M | $329.33M | $292.33M | $314.42M | $314.42M |
| Net PPE | $226.41M | $101.01M | $113.06M | $123.63M | $123.63M |
| -Gross PPE | $226.41M | $101.01M | $113.06M | $182.23M | $182.23M |
| Investments and Advances | $152.19M | $212.48M | $162.82M | $190.79M | $190.79M |
| -Available for Sale Securities | $140.70M | $190.60M | $141.26M | $155.25M | $155.25M |
| Other Non-Current Assets | $17.61M | $15.84M | $16.46M | – | – |
| Total Liabilities | $289.47M | $129.46M | $137.84M | $170.73M | $170.73M |
| Total Current Liabilities | $80.31M | $79.39M | $76.45M | $103.88M | $103.88M |
| Payables | $12.55M | $11.71M | $18.80M | $20.25M | $20.25M |
| -Accounts Payable | $12.55M | $11.71M | $18.80M | $20.25M | $20.25M |
| Current Accrued Expenses | $26.47M | $29.91M | $28.60M | $26.79M | $26.79M |
| Short-Term Debt and Capital Lease Obligation | $20.98M | $23.34M | $19.10M | $26.48M | $26.48M |
| -Current Capital Lease Obligation | $20.98M | $23.34M | $19.10M | $26.48M | $26.48M |
| Current Deferred Liabilities | $0.00 | $0.00 | $630,000.00 | $7.29M | $7.29M |
| Total Non-Current Liabilities | $209.17M | $50.07M | $61.40M | $66.85M | $66.85M |
| Long Term Debt and Capital Lease Obligation | $209.17M | $50.07M | $61.40M | $66.85M | $66.85M |
| -Long Term Debt | $73.73M | – | – | – | – |
| -Long Term Capital Lease Obligation | $135.43M | $50.07M | $61.40M | $66.85M | $66.85M |
| Total Equity | $613.09M | $727.71M | $620.94M | $671.39M | $671.39M |
| Stockholders' Equity | $613.09M | $727.71M | $620.94M | $671.39M | $671.39M |
| Capital Stock | $14,000.00 | $14,000.00 | $12,000.00 | $12,000.00 | $12,000.00 |
| -Common Stock | $14,000.00 | $14,000.00 | $12,000.00 | $12,000.00 | $12,000.00 |
| Additional Paid-In Capital | $3.54B | $3.52B | $3.31B | $3.26B | $3.26B |
| Retained Earnings | -$2.92B | -$2.79B | -$2.69B | -$2.59B | -$2.59B |
| Gains/Losses Not Affecting Retained Earnings | -$2.56M | -$1.03M | -$240,000.00 | $1.03M | $1.03M |
| -Accumulated Depreciation | – | – | – | -$58.61M | -$58.61M |
| Non-Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$85.43M | -$83.11M | -$117.35M | -$394.74M | -$69.29M |
| Net cash flow from continuing operations | -$85.43M | -$83.11M | -$117.35M | -$394.74M | -$69.29M |
| Net Income from Continuing Operations | -$127.49M | -$106.63M | -$96.23M | -$412.69M | -$95.79M |
| Gain/Loss from Continuing Operations | -$221,000.00 | – | – | $527,000.00 | – |
| Depreciation & Depletion & Amortization | $1.92M | $2.08M | $2.20M | $15.92M | $6.02M |
| Change in Working Capital | $16.09M | $4.15M | -$37.17M | -$73.75M | $494,000.00 |
| -Change in Receivables | -$178,000.00 | $1.81M | $337,000.00 | -$951,000.00 | $1.58M |
| -Change in Prepaid Assets | $3.20M | -$1.42M | -$12.97M | -$26.35M | -$8.69M |
| -Change in Payables and Accrued Expense | $1.84M | -$730,000.00 | -$13.37M | $716,000.00 | $15.99M |
| -Change in Other Current Assets | $10.29M | $10.12M | $8.34M | $35.90M | $10.23M |
| -Change in Other Current Liabilities | $940,000.00 | -$5.00M | -$12.84M | -$54.95M | -$4.64M |
| -Change In Other Working Capital | $0.00 | -$630,000.00 | -$6.66M | -$28.11M | -$13.98M |
| Net cash flow from investing | $61.94M | -$141.57M | $66.31M | $228.03M | $27.53M |
| Net Cash Flow from Continuing Investing Activities | $61.94M | -$141.57M | $66.31M | $228.03M | $27.53M |
| Net PPE Purchase and Sale | -$621,000.00 | -$1.72M | -$79,000.00 | -$1.13M | -$126,000.00 |
| Net Investment Purchase and Sale | $62.56M | -$139.85M | $66.39M | $229.16M | $27.66M |
| Financing Cash Flow | $73.46M | $196.12M | $33.57M | $131.49M | $1.98M |
| Net Cash Flow from Continuing Financing Activities | $73.46M | $196.12M | $33.57M | $131.49M | $1.98M |
| Net Common Stock Issuance | $0.00 | $194.58M | $33.57M | $128.18M | $0.00 |
| Proceeds from Stock Option Exercised | $0.00 | – | – | $3.31M | $1.98M |
| Ending Cash Balance | $171.50M | $121.53M | $150.10M | $167.57M | $167.57M |
| Net Change in Cash | $49.97M | -$28.57M | -$17.47M | -$35.22M | -$39.77M |
| Beginning Cash Balance | $121.53M | $150.10M | $167.57M | $202.79M | $207.34M |
| Free Cash Flow | -$86.32M | -$84.92M | -$117.43M | -$395.87M | -$69.41M |
No comments yet — be the first to weigh in on NTLA.
Sign in to join the discussion.